Comment on CMS proposed rule change issued 30 June 2025

London, UK, 1 July 2025 – Convatec notes the Centers for Medicare & Medicaid Services (CMS) proposed rule published on 30 June 2025 regarding the Durable Medical Equipment, Prosthetics, Orthotics, and Supplies competitive bidding program (DMEPOS CBP). Under the proposed rule, CMS seeks to include intermittent catheter and ostomy products in DMEPOS CBP.

Convatec will thoroughly review the scope of the proposal and any potential implications for patients and Healthcare Professionals (HCPs). We look forward to the opportunity to engage with CMS through its comment process and, if CMS were to move forward with this proposal, this would require consultation with stakeholders and further rule changes for each particular product over a longer time period.

Convatec is a leading, fully integrated developer, manufacturer and service provider of intermittent catheters and ostomy products in the United States through 180 Medical¹. We ensure that Medicare beneficiaries have access to the very best advice, service and product choice in the market, as evidenced by our best-in-class net promoter scores. As such, we are well positioned to adapt to any potential changes and to continue to grow in our market segments.

We believe that the Medicare payment systems should place value on responsible, innovative and high-quality product and service providers like Convatec to provide patient and HCP choice. We are firmly committed to innovation and service in the US and elsewhere as we deliver our vision of pioneering trusted medical solutions to improve the lives we touch.

Contacts

Analysts & investors: ir@convatec.com

Media: mediarelations@convatec.com

About Convatec 

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec’s revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com 

1. 180 Medical is a leading home services medical devices company in the United States, offering high-quality catheters and ostomy products.